Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $290.12M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.10M
Average 1.60M
Dividends
Autolus Therapeutics plc dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Autolus Therapeutics plc compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | 0.00% | $0.00 | 0.00% | 0.00% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | 0.00% | $0.00 | 0.00% | 0.00% |
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | 0.00% | $0.00 | 0.00% | 0.00% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | 0.00% | $0.00 | 0.00% | 0.00% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | 0.00% | $0.00 | 0.00% | 0.00% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | 0.00% | $0.00 | 0.00% | 0.00% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | 0.00% | $0.00 | 0.00% | 0.00% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | 0.00% | $0.00 | 0.00% | 0.00% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about AUTL's dividend, answered from reported figures.
Does AUTL stock pay dividends?
Autolus Therapeutics plc (AUTL) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is AUTL's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.